January 18, 2023
1 min read
Save
FDA gives tentative approval for extended-release capsules of MDD treatment
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
The FDA has granted tentative approval to Zydus Pharmaceuticals Inc. to market extended-release capsules of levomilnacipran, a treatment for major depressive disorder, the company announced in a press release.
The extended-release capsules will be available in 20 mg, 40 mg, 80 mg and 120 mg doses, the release stated.
Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor approved for the treatment of major depressive disorders in adults.